APA (7th ed.) Citation

Zhang, J., Li, J., Wu, L., Song, Y., Li, X., Gao, Q., . . . Dong, R. (2025). A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection. Clinical Pharmacology in Drug Development, 14(10), 754. https://doi.org/10.1002/cpdd.1569

Chicago Style (17th ed.) Citation

Zhang, Jianxiong, et al. "A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection." Clinical Pharmacology in Drug Development 14, no. 10 (2025): 754. https://doi.org/10.1002/cpdd.1569.

MLA (9th ed.) Citation

Zhang, Jianxiong, et al. "A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection." Clinical Pharmacology in Drug Development, vol. 14, no. 10, 2025, p. 754, https://doi.org/10.1002/cpdd.1569.